Spinal Muscular Atrophy

The introduction of 3 FDA-approved therapies for spinal muscular atrophy is enabling clinicians to treat the disease completely different from how it was handled in the past.

The new therapies for spinal muscular atrophy (SMA) have had such a profound impact on disease trajectory that classification terminology has been changed, said Vamshi Rao, MD, attending physician, Children’s Hospital of Chicago, and assistant professor, Northwestern University Feinberg School of Medicine.

Early intervention for spinal muscular atrophy (SMA) is crucial to reduce disability due to the disease, said Vamshi Rao, MD, attending physician, Children’s Hospital of Chicago; assistant professor, Northwestern University Feinberg School of Medicine.